Symmetry Partners’s Quest Diagnostics DGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
– Sell
-4,668
Closed -$639K – 205
2024
Q2
$639K Sell
4,668
-200
-4% -$27.4K 0.03% 231
2024
Q1
$648K Hold
4,868
– – 0.05% 246
2023
Q4
$670K Sell
4,868
-304
-6% -$40K 0.04% 227
2023
Q3
$630K Sell
5,172
-852
-14% -$114K 0.03% 255
2023
Q2
$847K Hold
6,024
– – 0.04% 211
2023
Q1
$852K Buy
6,024
+250
+4% +$35.8K 0.05% 206
2022
Q4
$903K Hold
5,774
– – 0.05% 196
2022
Q3
$708K Hold
5,774
– – 0.05% 228
2022
Q2
$768K Hold
5,774
– – 0.05% 222
2022
Q1
$790K Hold
5,774
– – 0.05% 245
2021
Q4
$999K Hold
5,774
– – 0.06% 210
2021
Q3
$815K Hold
5,774
– – 0.05% 271
2021
Q2
$762K Sell
5,774
-1,153
-17% -$151K 0.05% 295
2021
Q1
$889K Sell
6,927
-1,661
-19% -$205K 0.06% 230
2020
Q4
$1.02M Sell
8,588
-669
-7% -$81.6K 0.08% 178
2020
Q3
$1.06M Buy
9,257
+3,946
+74% +$466K 0.09% 151
2020
Q2
$605K Buy
5,311
+779
+17% +$82.6K 0.08% 116
2020
Q1
$364K Buy
+4,532
New +$469K 0.08% 171
2019
Q2
– Sell
-524
Closed -$47K – 349
2019
Q1
$47K Buy
524
+231
+79% +$20K 0.01% 417
2018
Q4
$24K Buy
+293
New +$27.5K 0.01% 374

Other funds holding DGX

Symmetry Partners's DGX Position: Q3 2024 in Review

Symmetry Partners sold out of Quest Diagnostics (DGX) in Q3 2024, closing a stake of 4,668 shares — an estimated $639K sold.

Symmetry Partners first reported a position in DGX in Q4 2018 and held it in 20 quarters. The position peaked at $1.06M in Q3 2020. 847 funds tracked by Wall St. Rank hold DGX as of Q3 2024.

  • Symmetry Partners reported no remaining Quest Diagnostics position as of Q3 2024 after selling out during the quarter.
  • Symmetry Partners sold 4,668 Quest Diagnostics shares in Q3 2024, an estimated $639K.
  • Symmetry Partners first reported a position in Quest Diagnostics in Q4 2018 and held it in 20 quarters.
  • Symmetry Partners's Quest Diagnostics position peaked at $1.06M in Q3 2020.
  • 847 funds tracked by Wall St. Rank held Quest Diagnostics as of Q3 2024.

Based on Symmetry Partners's 13F filing for Q3 2024, filed 29 Oct 2024.